abrdn plc Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS)

abrdn plc grew its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 38.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 179,060 shares of the company’s stock after purchasing an additional 50,000 shares during the period. abrdn plc’s holdings in NewAmsterdam Pharma were worth $4,602,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $503,000. HB Wealth Management LLC purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $224,000. JPMorgan Chase & Co. increased its holdings in NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock worth $371,000 after buying an additional 14,280 shares in the last quarter. Finally, Barclays PLC raised its position in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

NAMS has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $41.60.

Insider Transactions at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares of the company’s stock, valued at $295,537,065.66. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 446,730 shares of company stock worth $11,438,695 in the last 90 days. 19.50% of the stock is currently owned by insiders.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $20.19 on Monday. NewAmsterdam Pharma has a 12-month low of $15.19 and a 12-month high of $27.29. The firm has a 50 day moving average of $23.59 and a 200 day moving average of $20.08.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.